Crossmark

VR-SOAP, a modular virtual reality treatment for improving social activities and participation of young people with psychosis: a study protocol for a single-blind multi-centre randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-023-07241-z

Published Online: 2023-04-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Meins, Ivo Alexander https://orcid.org/0000-0001-7279-6456
Muijsson-Bouwman, Dauw Catharina

Nijman, Saskia Anne

Greaves-Lord, Kirstin

Veling, Wim

Pijnenborg, Gerdina Hendrika Maria

van der Stouwe, Elisabeth Christine Dorothée
Funding

Funding for this research was provided by:

NWO (Aut.17.003.6617)

GGZ Drenthe
License Information

Text and Data Mining valid from 2023-04-15

Version of Record valid from 2023-04-15
More Information

Article History

Received: 2 January 2023

Accepted: 13 March 2023

First Online: 15 April 2023

Declarations

:

: All participants will provide written consent. The trial has been approved by the Medical Ethical Committee of the University Medical Center Groningen (METc file number: 2021/351, ABR: NL69628.042.21, protocol version 5, September 2022).

: Not applicable.

: WV is a cofounder of VRelax BV, the company that has developed VR relaxation software in collaboration with UMCG, and holds shares in VRelax BV. The other authors declare that they have no competing interests<b>.</b>

Document is current

Any future updates will be listed below